Thirty-two million Americans currently have health conditions linked to genetic defects, nearly all of which can be corrected by genetic editing with CRISPR-Cas9 technology. Opponents of gene editing abound, from those who point to their potential role in increasing the privilege gap between the rich and poor, to people who object morally to the idea of humans meddling with their own DNA, to pharmaceutical companies whose profits would be threatened by a reduced need for medication. However, after analysis of the ethicality of genetic editing technology with the frameworks of common good, utilitarianism, and fairness, it is evident that the eventual species-scale benefits that will be brought about by the technology outweigh its risks and flaws.
